Paper Search Console

Home Search Page Alphabetical List About Contact

Journal Title

Title of Journal: Abdom Imaging

Search In Journal Title:

Abbravation: Abdominal Imaging

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1007/s003910070015

Search In DOI:

ISSN

1432-0509

Search In ISSN:
Search In Title Of Papers:

Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal cancer

Authors: Michael H. Rosenthal, Kyung Won Kim, Charles S. Fuchs, Jeffrey A. Meyerhardt, Nikhil H. Ramaiya,

Publish Date: 2014/06/07
Volume: 39, Issue:6, Pages: 1261-1266
PDF Link

Abstract

KRAS oncogene testing is recommended in all patients with metastatic colorectal cancer due to its impact on treatment selection, but we do not know if KRAS genotype affects extent or pattern of metastases. We investigated whether the initial radiographic distribution of disease varies by KRAS genotype in stage IV colorectal cancer.This retrospective study of 65 patients with stage IV colorectal cancer was derived from an institutional clinical trials database. Inclusion criteria required KRAS testing and pretreatment CT studies to be available. Disease burden was characterized by two radiologists.Univariate analysis showed that there was no significant difference in the initial distribution of disease between KRAS mutant and wild type tumors (P > 0.05). Exploratory analyses showed that patients with poorly differentiated histology had a statistically significant increase in hepatic metastases in the presence of KRAS mutations vs. KRAS wild type genotype (median 5.0 vs. 0.5, P = 0.02).No overall difference was found in the initial radiographic distribution of disease between KRAS mutant and wild type colorectal cancers. Patients with both poorly differentiated histology and KRAS mutations had more liver metastases in subgroup analyses.This work was supported in part by National Institutes of Health Grants 5P50CA127003, R01CA149222, R01CA118553, and National Cancer Institute Cancer Center Support Grant 5P30CA06516. We thank Dana-Farber/Harvard Cancer Center in Boston, MA, for the use of the Pathology Specimen Locator Core, which provided data on KRAS mutation testing.


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:


Search Result:



Help video to use 'Paper Search Console'